<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2340-9894</journal-id>
<journal-title><![CDATA[Ars Pharmaceutica (Internet)]]></journal-title>
<abbrev-journal-title><![CDATA[Ars Pharm]]></abbrev-journal-title>
<issn>2340-9894</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Granada]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2340-98942025000300288</article-id>
<article-id pub-id-type="doi">10.30827/ars.v66i3.31529</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Formulation and evaluation of stiripentol oral suspension]]></article-title>
<article-title xml:lang="es"><![CDATA[Formulación y evaluación de la suspensión oral de estiripentol]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Kandekar]]></surname>
<given-names><![CDATA[Ujjwala]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bitale]]></surname>
<given-names><![CDATA[Dinesh]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Chounde]]></surname>
<given-names><![CDATA[Limbaji]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gaikwad]]></surname>
<given-names><![CDATA[Ajit]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,JSPM&#8217;s Rajarshi Shahu College of Pharmacy &amp; Research Tathawade Department of Pharmaceutics ]]></institution>
<addr-line><![CDATA[Pune Maharashtra ]]></addr-line>
<country>India</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Callidus Research Laboratories Pvt. Ltd  ]]></institution>
<addr-line><![CDATA[Pune Maharashtra]]></addr-line>
<country>India</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2025</year>
</pub-date>
<volume>66</volume>
<numero>3</numero>
<fpage>288</fpage>
<lpage>300</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S2340-98942025000300288&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S2340-98942025000300288&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S2340-98942025000300288&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction:  The current research work was carried out to develop a stable and effective suspension of stiripentol for treating epilepsy.  Method:  FT-IR study was used to evaluate the compatibility between drug and excipient and the physical appearance of drug and excipient mixture was also examined after one month of stability study. The suspension was prepared by a mechanical stirrer and evaluated for viscosity, pH, sedimentation volume, zeta potential and in-vitro drug release studies. The optimized formulation was further evaluated for zeta potential and polydispersity index.  Results:  FT-IR results confirmed the compatibility of drug and excipients. The physical appearance of the mixture was not altered during the accelerated storage conditions. Viscosity, pH and sedimentation volume of formulation ranged between 22.92 ±1.2 to 54.8 ± 2.1 cPs, 5.32 ± 0.04 to 6.01 ± 0.1 and 83.19 ± 0.9 % to 98.87 ± 1.2 % respectively. The zeta potential and polydispersity index of the optimized formulation was -52.1 mV and 0.198 respectively. These results were indicative of stable monodispersed suspension. The optimized formulation was stable at higher temperatures, humidity and in the presence of light, indicative of good shelf-life.  Conclusions: The study demonstrated that stiripentol oral suspension can be formulated as a stable and effective dosage form for the treatment of epilepsy.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción:  El trabajo de investigación se llevó a cabo para desarrollar una suspensión estable y eficaz de estiripentol para el tratamiento de la epilepsia.  Método:  Se utilizó el estudio FT-IR para evaluar la compatibilidad entre el fármaco y el excipiente y también se examinó la apariencia física de la mezcla del fármaco y el excipiente después de un mes de estudio de estabilidad. La suspensión se preparó mediante un agitador mecánico y se evaluó la viscosidad, el pH, el volumen de sedimentación, el potencial zeta y los estudios de liberación de fármaco in vitro. La formulación optimizada se evaluó adicionalmente para determinar el potencial zeta y el índice de polidispersidad.  Resultados:  Los resultados de FT-IR confirmaron la compatibilidad del fármaco y los excipientes. La apariencia física de la mezcla no se alteró durante las condiciones de almacenamiento aceleradas. La viscosidad, el pH y el volumen de sedimentación de la formulación oscilaron entre 22,92 ±1,2 cPs y 54,8 ± 2,1 cPs; 5,32 ± 0,04 y 6,01 ± 0,1 y 83,19 ± 0,9 % y 98,87 ± 1,2 % respectivamente. El potencial zeta y el índice de polidispersidad de la formulación optimizada fueron -52,1 mV y 0,198 respectivamente. Estos resultados fueron indicativos de una suspensión monodispersa estable. La formulación optimizada fue estable a temperaturas y humedad más altas y en presencia de luz, lo que indica una buena vida útil.  Conclusiones:  El estudio demostró que la suspensión oral de estiripentol puede formularse como una forma farmacéutica estable y eficaz para el tratamiento de la epilepsia.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Estiripentol]]></kwd>
<kwd lng="es"><![CDATA[suspensión]]></kwd>
<kwd lng="es"><![CDATA[viscosidad]]></kwd>
<kwd lng="es"><![CDATA[volumen de sedimentación]]></kwd>
<kwd lng="es"><![CDATA[potencial zeta]]></kwd>
<kwd lng="en"><![CDATA[Stiripentol]]></kwd>
<kwd lng="en"><![CDATA[suspension]]></kwd>
<kwd lng="en"><![CDATA[viscosity]]></kwd>
<kwd lng="en"><![CDATA[sedimentation volume]]></kwd>
<kwd lng="en"><![CDATA[zeta potential]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hameed]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Saleem]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mirza]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mustafa]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Qamar Ul]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Characterisation of ictal and interictal states of epilepsy: A system dynamic approach of principal dynamic modes analysis]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2018</year>
<volume>13</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rho]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Sankar]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The pharmacologic basis of antiepileptic drug action]]></article-title>
<source><![CDATA[Epilepsia]]></source>
<year>1999</year>
<volume>40</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1471-83</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fisher]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effects of stiripentol on GABA(A) receptors]]></article-title>
<source><![CDATA[Epilepsia]]></source>
<year>2011</year>
<volume>52</volume>
<numero>Suppl 2</numero>
<issue>Suppl 2</issue>
<page-range>76-8</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Uchida]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Terada]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Madokoro]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stiripentol for the treatment of super-refractory status epilepticus with cross-sensitivity]]></article-title>
<source><![CDATA[Acta Neurol Scand]]></source>
<year>2018</year>
<volume>137</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>432-7</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chiron]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Chemaly]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Chancharme]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Nabbout]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Initiating stiripentol before 2 years of age in patients with Dravet syndrome is safe and beneficial against status epilepticus]]></article-title>
<source><![CDATA[Dev Med Child Neurol]]></source>
<year>2023</year>
<volume>65</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1607-16</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wheless]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Weatherspoon]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of Stiripentol in Dravet syndrome: A guide for clinicians]]></article-title>
<source><![CDATA[Pediatr Neurol]]></source>
<year>2024</year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Xiao]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stiripentol enteric solid dispersion-loaded effervescent tablets: Enhanced dissolution, stability, and absorption]]></article-title>
<source><![CDATA[AAPS PharmSciTech]]></source>
<year>2022</year>
<volume>23</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vázquez-Blanco]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[González-Freire]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Dávila-Pousa]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Crespo-Diz]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[pH determination as a quality standard for the elaboration of oral liquid compounding formula]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2018</year>
<volume>42</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>221-7</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oppong]]></surname>
<given-names><![CDATA[EE]]></given-names>
</name>
<name>
<surname><![CDATA[Osei-Asare]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Klu]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of the suspending properties of shea tree gum]]></article-title>
<source><![CDATA[Int J Pharm Pharm Sci]]></source>
<year>2016</year>
<volume>8</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>409-13</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[PP]]></given-names>
</name>
<name>
<surname><![CDATA[Mashru]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Formulation and evaluation of taste masked oral reconstitutable suspension of primaquine phosphate]]></article-title>
<source><![CDATA[AAPS PharmSciTech]]></source>
<year>2008</year>
<volume>9</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1025-30</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giupponi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pagonabarraga]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Determination of the zeta potential for highly charged colloidal suspensions]]></article-title>
<source><![CDATA[Philos Trans A Math Phys Eng Sci]]></source>
<year>2011</year>
<volume>369</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>2546-54</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Damor]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Design and development of dual release reconstitutable oral suspension of cefpodoxime proxetil for pediatric patient using risk-based quality by design approach]]></article-title>
<source><![CDATA[J Pharm Innov]]></source>
<year>2022</year>
<volume>17</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>955-78</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rahman]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Hasan]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Nitai]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recent developments of carboxymethyl cellulose]]></article-title>
<source><![CDATA[Polymers]]></source>
<year>2021</year>
<volume>13</volume>
<numero>8</numero>
<issue>8</issue>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Almutairi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[D R L]]></surname>
</name>
<name>
<surname><![CDATA[Ghabbour]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Joe]]></surname>
<given-names><![CDATA[IH]]></given-names>
</name>
<name>
<surname><![CDATA[Attia]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Spectroscopic identification, structural features, Hirshfeld surface analysis and molecular docking studies on stiripentol: An orphan antiepileptic drug]]></article-title>
<source><![CDATA[Journal of Molecular Structure]]></source>
<year>2018</year>
<volume>1180</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pongjanyakul]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Puttipipatkhachorn]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Polymer-magnesium aluminum silicate composite dispersions for improved physical stability of acetaminophen suspensions]]></article-title>
<source><![CDATA[AAPS PharmSciTech]]></source>
<year>2009</year>
<volume>10</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>346-54</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Attebäck]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hedin]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Mattsson]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Formulation optimization of extemporaneous oral liquids containing naloxone and propranolol for pediatric use]]></article-title>
<source><![CDATA[Sci Pharm]]></source>
<year>2022</year>
<volume>90</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Owusu]]></surname>
<given-names><![CDATA[FW]]></given-names>
</name>
<name>
<surname><![CDATA[Asare]]></surname>
<given-names><![CDATA[CO]]></given-names>
</name>
<name>
<surname><![CDATA[Enstie]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Formulation and in vitro evaluation of oral capsules and suspension from the ethanolic extract of cola nitida seeds for the treatment of diarrhea]]></article-title>
<source><![CDATA[Biomed Res Int]]></source>
<year>2021</year>
<volume>2021</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-7</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Kandekar]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optimizing fluconazole-embedded transfersomal gel for enhanced antifungal activity and compatibility studies]]></article-title>
<source><![CDATA[Front Pharmacol]]></source>
<year>2024</year>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Júnior]]></surname>
<given-names><![CDATA[JAA]]></given-names>
</name>
<name>
<surname><![CDATA[Baldo]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The behavior of zeta potential of silica suspensions]]></article-title>
<source><![CDATA[New J GC]]></source>
<year>2014</year>
<volume>4</volume>
<numero>02</numero>
<issue>02</issue>
<page-range>1-9</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Adeleke]]></surname>
<given-names><![CDATA[OA]]></given-names>
</name>
<name>
<surname><![CDATA[Hayeshi]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
<name>
<surname><![CDATA[Davids]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development and evaluation of a reconstitutable dry suspension containing isoniazid for flexible pediatric dosing]]></article-title>
<source><![CDATA[Pharmaceutics]]></source>
<year>2020</year>
<volume>12</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Santoveña]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Suárez-González]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Martín-Rodríguez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fariña]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Formulation design of oral pediatric Acetazolamide suspension: dose uniformity and physico-chemical stability study]]></article-title>
<source><![CDATA[Pharm Dev Technol]]></source>
<year>2017</year>
<volume>22</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>191-7</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
